Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Reexamination Certificate
2004-05-24
2009-11-17
Landsman, Robert (Department: 1646)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
C530S388220
Reexamination Certificate
active
07618632
ABSTRACT:
The present invention provides novel isolated and purified polynucleotides and polypeptides related to a novel ligand for glucocorticoid-induced TNF receptor (GITR). The invention also provides antibodies to the GITR ligand (GITRL). The present invention also is directed to novel methods for diagnosing, prognosing, monitoring the progress of, and treating disorders arising from disregulation of the immune system (e.g., autoimmune disorders, inflammatory diseases, and transplant rejection, and cancers and infectious diseases) using GITRL and/or modulators of GITRL. The present invention is further directed to novel therapeutics and therapeutic targets and to methods of screening and assessing test compounds for the intervention (treatment) and prevention of said disorders arising from disregulation of the immune system, as related to GITRL and GITR.
REFERENCES:
patent: 5593972 (1997-01-01), Weiner et al.
patent: 5624821 (1997-04-01), Winter et al.
patent: 5648260 (1997-07-01), Winter et al.
patent: 5714147 (1998-02-01), Capon et al.
patent: 5998171 (1999-12-01), Yu et al.
patent: 6077673 (2000-06-01), Chenchick et al.
patent: 6406867 (2002-06-01), Yu et al.
patent: 6506559 (2003-01-01), Fire et al.
patent: 6521742 (2003-02-01), Yu et al.
patent: 2002/0146389 (2002-10-01), Ashkenazi et al.
patent: 2003/0133936 (2003-07-01), Byrne et al.
patent: WO 98/24895 (1998-06-01), None
Merrill JT. Emergence of targeted immune therapies for systemic lupus. Expert Opin. Emerging Drugs. 2005. vol. 10, No. 1, pp. 53-65.
Galon J., et al. TNFSF1A mutations and autoinflammatory syndroms. Current Opinion in Immunology. 2000. vol. 12, p. 479-486.
Arts et al. “Adenoviral Vectors Expressing siRNAs for Discovery and Validation of Gene Function” Genome Res. 13:2325-32 (2003).
Aseffa et al. “The Early IL-4 Response toLeishmania majorand the Resulting Th2 Cell Maturation Steering Progressive Disease in BALB/c Mice are Subject to the control of Regulatory CD4(+)CD25(+) T Cells1” J. Immunol. 169:3232-41 (2002).
Banchereau and Steinman “Dendritic Cells and the Control of Immunity” Nature 392:245-52 (1998).
Bass “The Short Answer” Nature 411:428-29 (2001).
Belkaid et al. “CD4(+)CD25(+) Regulatory T cells ControlLeishmania majorPersistence and Immunity” Nature 420:502-07 (2002).
Bockamp et al. “Of Mice and Models: Improved Animal Models for Biomedical Research” Physiol. Genomics 11(3):115-32 (2002).
Brenne et al. “Interleukin-21 is a Growth and Survival Factor for Human Myeloma Cells” Blood 99(10):3756-62 (2002).
Cerundolo et al. “Dendritic Cells: A Journey from Laboratory to Clinic” Nat. Immunol. 5(1):7-10 (2004).
Chothia and Lesk “Canonical Structures for the Hypervariable Regions of Immunoglobulins” J. Mol. Biol. 196:901-17 (1987).
Claros and von Heijne “TopProd II: an improved software of membrane protein structure predictions” Comput. Appl. Biosci. 10:685-86 (1994).
Croft “Co-Stimulatory Members of the TNFR Family: Keys to Effective T-Cell Immunity” Nat. Rev. Immunol. 3:609-20 (2003).
Degermann et al. “On the Various Manifestations of Spontaneous Autoimmune Diabetes in Rodent Models” Eur. J. Immunol. 24:3155-66 (1994).
Desbarats et al. “Newly Discovered Role for Fas Ligand in the Cell-Cycle Arrest of CD4+ T Cells” Nat. Med. 4:1377-82 (1998).
Dorn et al. “siRNA Relieves Chronic Neuropathic Pain” Nucleic Acids Res. 32(5):e49(pp. 1-6) (2004).
Elbashir et al. “Functional Anatomy of siRNAs for Mediating Efficient PNAi inDrosophila melanogasterEmbryo Lysate” EMBO J. 20(23):6877-88 (2001).
Elbashir et al. “Duplexes of 21-Nucleotide RNAs Mediate RNA Interference in Cultured Mammalian Cells” Nature 411:494-98 (2001).
Galderisi et al. “Antisense Oligonucleotides as Therapeutic Agents” J. Cell. Physiol. 181:251-57 (1999).
Gavin et al. “Homeostasis and Anergy of CD4+CD25+ Suppressor T Cells In Vivo” Nat. Immunol. 3(1): 33-41 (2002).
Gilfillan et al. “Expression of the Costimulatory Receptor CD30 is Regulated by Both CD28 and Cytokines” J. Immunol. 160(5):2180-87 (1998).
Giulietti et al. “An Overview of Real-Time Quantitative PCR: Applications to Quantify Cytokine Gene Expression” Methods 25(4):386-401 (2001).
Gurney et al. “Identification of a New Member of the Tumor Necrosis Factor Family and Its Receptor, a Human Ortholog of Mouse GITR” Curr. Biol. 9(4):215-18 (1999).
Han et al. “Extracellular Matrix Protein 1 (ECM1) has Angiogenic Properties and is Expressed by Breast Tumor Cells” FASEB J. 15(6):988-94 (2001).
Heasman “Morpholino Oligos: Making Sense of Antisense?” Dev. Biol. 243(2):209-14 (2002).
Heid et al. “Real Time Quantitative PCR” Genome Res. 6(10):986-94 (1996).
Henikoff and Henikoff “Amino Acid Substitution Matrices from Protein Blocks” Proc. Natl. Acad. Sci. USA 89:10915-19 (1992).
Hisaeda et al. “Escape of Malaria Parasites from Host Immunity Requires CD4+CD25+ Regulatory T Cells” Nat. Med. 10(1):29-30 (2004).
Ji et al. “Cutting edge: the natural ligand for glucocorticoid-induced TNF receptor-related protein abrogates regulatory T cell suppression” J. Immunol. 172:5823-27 2004.
Jordan et al. “Thymic Selection of CD4+CD25+ Regulatory T Cells Induced by an Agonist Self-peptide” Nat. Immunol. 2(4):301-06 (2001).
Kim et al. “Cloning and Characterization of GITR Ligand” Genes Immun. 4:564-69 (2003).
Knauert and Glazer “Triplex Forming Oligonucleotides: Sequence-specific Tools for Gene Targeting” Hum. Mol. Genet. 10:2243-51 (2001).
Ko et al. “Immunotherapy of Malignant Diseases” Int. Arch. Allergy Immunol. 132(4):294-309 (2003).
Kumanogoh et al. “Increased T Cell Autoreactivity in the Absence of CD40-CD40 Ligand Interactions: A Role of CD40 in Regulatory T Cell Development” J. Immunol. 166:353-60 (2001).
Kursar et al. “Regulatory CD4+CD25+ T Cells Restrict Memory CD8+ T Cell Responses” J. Exp. Med. 196(12):1585-92 (2002).
Kuwana “Induction of Anergic and Regulatory T Cells by Plasmacytoid Dendritic Cells and Other Dendritic Cell Subsets” Hum. Immunol. 63:1156-63 (2002).
Kwon et al. “Identification of a Novel Activation-inducible Protein of the Tumor Necrosis Factor Receptor Superfamily and Its Ligand” J. Biol. Chem. 274(10):6056-61 (1999).
Lu and Thomson “Manipulation of Dendritic Cells for Tolerance Induction in Transplantation and Autoimmune Disease” Transplantation 73:S19-S22 (2002).
Lundgren et al. “Helicobacter Pylori-specific CD4+CD25(high) Regulatory T Cells Suppress Memory T-cell Responses to H. Pylori in Infected Individuals” Infect. Immun. 71(4):1755-62 (2003).
Maloy et al. “CD4+CD25+ T(R) Cells Suppress Innate Immune Pathology Through Cytokine-dependent Mechanisms” J. Exp. Med. 197(1):111-19 (2003).
Mancini et al. “The Management of Immunosuppression: The Art and The Science” Crit. Care. Nurs. Q. 27:61-64 (2004).
McHugh and Shevach “The Role of Suppressor T Cells in Regulation of Immune Responses” J. Allergy Clin. Immunol. 110:693-702 (2002).
McHugh et al. “CD4(+)CD25(+) Immunoregulatory T Cells: Gene Expression Analysis Reveals a Functional Role for the Glucocorticoid-induced TNF Receptor” Immunity 16:311-23 (2002).
Micklefield “Backbone Modification of Nucleic Acids: Synthesis, Structure and Therapeutic Applications” Curr. Med. Chem. 8:1157-79 (2001).
Mullah et al. “Efficient Synthesis of Double Dye-labeled Oligodeoxyribonucleotide Probes and their application in a Real Time PCR Assay” Nucleic Acids Res. 26(4)1026-31 (1998).
Nakano et al. “CD11c(+)B220(+)Gr-1(+) Cells in Mouse Lymph Nodes and Spleen Display Characteristics of Plasmacytoid Dendritic Cells” J. Exp. Med. 194(8):1171-78 (2001).
Byrne Michael Chapman
Carreno Beatriz M.
Collins Mary
McHugh Rebecca Suzanne
Reddy Padmalatha S.
Fitzpatrick ,Cella, Harper & Scinto
Hissong Bruce D
Landsman Robert
The United States of America as represented by the Secretary of
Wyeth
LandOfFree
Method of treating or ameliorating an immune cell associated... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of treating or ameliorating an immune cell associated..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of treating or ameliorating an immune cell associated... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4088159